Evidence map›Paper›PMID 41469153›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

First-in-Human Study of the Carbohydrate Nanoparticle

Aileen O'Shea, Andrew J M Lewis, Peter Caravan, David Izquierdo-Garcia, Mariane Le Fur, Onofrio A Catalano, Sydney B Montesi, Jeremy M Quintana, Jonathan C T Carlson, John M Dubach and 7 more

Abstract readClinical Trial
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Pharmaceuticals (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Aileen O'SheaCenter for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.
Andrew J M LewisCenter for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.
Peter CaravanDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
David Izquierdo-GarciaDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
Mariane Le FurDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
Onofrio A CatalanoDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
Sydney B MontesiDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Jeremy M QuintanaCenter for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.
Jonathan C T CarlsonCenter for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.
John M DubachDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
Cesar M CastroCenter for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.
Mislav BobićDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts; and.
Carlos Huesa-BerralDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts; and.
Thomas S C NgCenter for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.
Alejandro BertoletDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts; and.
Matthias NahrendorfCenter for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.
Ralph WeisslederCenter for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts; rweissleder@mgh.harvard.edu.

Funding

Radiation dosimetry for alpha-particle radiopharmaceutical therapy and application to pediatric neuroblastomaR00CA267560 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BERTOLET REINA, ALEJANDRO · 2023 to 2025
$721k
British Heart Foundation FS/ICRF/24/2611British Heart Foundation FS/TF/20/33001NCI NIH HHS R00 CA267560
6 · The paper itself

Abstract

Macrophage density and phenotype are key components of the innate immune response and have been implicated in the outcomes and progression of cancer and autoimmune diseases. The ability to quantify and perform temporospatial analysis of macrophages could enable more specific therapeutic interventions. Macrin, a 17-nm nanoparticle, has shown high selectivity for macrophage accumulation in preclinical models of disease. The purpose of this first-in-human study was to evaluate the biodistribution, dosimetry, and safety of

Indexed as

Copper RadioisotopesNanoparticlesThiosemicarbazonesAdultAgedCoordination ComplexesFemaleHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyTissue DistributionCoordination ComplexesCopper-64copper (II) diacetyl-di(N(4)-methylthiosemicarbazone)Copper RadioisotopesThiosemicarbazonescancerhumanmacrophagesnanoparticlesPET imagingradiation dosimetrytumor-associated macrophages

Identifiers

PMID41469153
PMCPMC13671009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.